Kabeya Mwintshi, MD
Nephrology · Saint Louis, MONPI 1316994460
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,411 of the $25,387 with a category attached, or 72.5%. Baxter Healthcare accounts for 85.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $11,927 and has fallen 95.7% since, to $518 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $130.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$22K
- AstraZeneca$876
- Amgen$743
- OPKO Pharmaceuticals, LLC$290
- GSK$265
- Akebia Therapeutics Inc$208
- plus $1K from 18 others
What the payments were for
- Consulting fees$18,41173%
- Travel & lodging$2,94812%
- Food & beverage$3,90915%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 32 | $21,705 |
| AstraZeneca(2 entities) | 30 | $876 |
| Amgen(2 entities) | 33 | $743 |
| OPKO Pharmaceuticals, LLC | 14 | $290 |
| GSK | 11 | $265 |
| Akebia Therapeutics Inc | 14 | $208 |
| Otsuka America Pharmaceutical, Inc. | 9 | $172 |
| Bayer | 5 | $164 |
| Vifor Pharma, Inc. | 9 | $144 |
| Mallinckrodt Enterprises LLC | 6 | $144 |
| Mallinckrodt Hospital Products Inc. | 7 | $125 |
| Vantive US Healthcare LLC | 1 | $117 |
| Fresenius USA Marketing, Inc. | 6 | $97 |
| Travere Therapeutics, Inc. | 4 | $65 |
| Ardelyx, Inc. | 2 | $50 |
| Novo Nordisk | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Novartis | 2 | $35 |
| Boehringer Ingelheim | 1 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Biobeat USA Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,387 in reported general payments places this provider in the 90th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 14 | $265,789 |
| VelphoroSucroferric Oxyhydroxide | 23 | $98,626 |
| AuryxiaFerric Citrate | 41 | $53,592 |
| LokelmaSodium Zirconium Cyclosilicate | 48 | $38,033 |
| FarxigaDapagliflozin Propanediol | 47 | $29,119 |
| Sevelamer Carbonate | 145 | $23,060 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $11,640 |
| Furosemide | 304 | $2,159 |
| Losartan Potassium | 226 | $1,806 |
| Nifedipine ErNifedipine | 69 | $1,488 |
| Hydralazine Hcl | 89 | $1,481 |
| Carvedilol | 136 | $1,331 |
| Midodrine Hcl | 60 | $1,227 |
| Calcium Acetate | 20 | $1,148 |
| Amlodipine Besylate | 164 | $1,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $172 | $265,78914 claims |
| Fresenius USA Marketing, Inc.Velphoro | $97 | $98,62623 claims |
| AstraZenecaLokelma, Farxiga | $876 | $67,15295 claims |
| Akebia Therapeutics IncAuryxia | $208 | $53,59241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 253 nephrology providers in Missouri.
Other nephrology in Saint Louis
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Krista LentineSaint Louis$86K
- Rowena Delos SantosSaint Louis$30K
- Naoka MurakamiSaint Louis$24K
- Benjamin HumphreysSaint Louis$13K
- Leslie GewinSaint Louis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.